Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | CCR8 | P51685 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24916774 | 0.81 | CCR1 (0.52) | SMN1; SMN2CCR1CCR8NOS2NOS3 | |
| SCHEMBL30201993 | 0.81 | CCR1 (0.52) | SMN1; SMN2CCR1CCR8NOS2NOS3 | |
| SCHEMBL6193822 | 0.81 | SMN1; SMN2 (0.45) | SMN1; SMN2CCR1CCR8NOS2NOS3 | |
| SCHEMBL17429701 | 0.80 | CCR1 (0.43) | SMN1; SMN2CCR1CCR8NOS2NOS3 | |
| SCHEMBL10144469 | 0.79 | KCNH2 (0.54) | SMN1; SMN2CCR1CCR8NOS2NOS3 | |
| SCHEMBL7029816 | 0.78 | KCNH2 (0.35) | NOS2KCNH2NOS1ALDH1A1NPSR1 | |
| SCHEMBL832445 | 0.78 | SMN1; SMN2 (0.45) | SMN1; SMN2CCR1CCR8NOS2NOS3 | |
| SCHEMBL7799450 | 0.77 | NOS2 (0.43) | NOS2NOS3KCNH2NOS1GRM4 | |
| SCHEMBL7798225 | 0.76 | PDE10A (0.37) | NOS2KCNH2NOS1 | |
| SCHEMBL427622 | 0.75 | KCNH2 (0.52) | SMN1; SMN2CCR1CCR8NOS2NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1735352-B1 | LATENT, HIGH-ACTIVITY OLEFIN METATHESIS CATALYSTS CONTAINING AN N-HETEROCYCLIC CARBENE LIGAND | CALIFORNIA INST OF TECHN (US) | 2019-08-21 | — | — | EP | disclosed |
| US-9238709-B2 | Latent, high-activity olefin metathesis catalysts containing an N-heterocyclic carbene ligand | MATERIA, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20150141603-A1 | LATENT, HIGH-ACTIVITY OLEFIN METATHESIS CATALYSTS CONTAINING AN N-HETEROCYCLIC CARBENE LIGAND | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-21 | — | — | US | disclosed |
| US-8871879-B2 | Latent, high-activity olefin metathesis catalysts containing an N-heterocyclic carbene ligand | MATERIA, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130296511-A1 | LATENT, HIGH-ACTIVITY OLEFIN METATHESIS CATALYSTS CONTAINING AN N-HETEROCYCLIC CARBENE LIGAND | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-11-07 | — | — | US | disclosed |
| CN-101090915-A | Latent, high-activity olefin metathesis catalysts containing an n-heterocyclic carbene ligand | CALIFORNIA INST OF TECHN (US) | 2007-12-19 | — | — | CN | disclosed |
| EP-1735352-A2 | LATENT, HIGH-ACTIVITY OLEFIN METATHESIS CATALYSTS CONTAINING AN N-HETEROCYCLIC CARBENE LIGAND | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20050261451-A1 | Latent, high-activity olefin metathesis catalysts containing an N-heterocyclic carbene ligand | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2005-11-24 | — | — | US | disclosed |
| WO-2005094345-A2 | LATENT, HIGH-ACTIVITY OLEFIN METATHESIS CATALYSTS CONTAINING AN N-HETEROCYCLIC CARBENE LIGAND | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2005-10-13 | — | — | WO | disclosed |
| EP-0993466-B1 | RUTHENIUM AND OSMIUM CATALYSTS | CIBA SC HOLDING AG (CH) | 2003-11-05 | — | — | EP | disclosed |
| US-6306987-B1 | Ruthenium and osmium catalysts | CIBA SPECIALTY CHEMICALS CORPORATION | 2001-10-23 | — | — | US | disclosed |
| EP-0993466-A1 | RUTHENIUM AND OSMIUM CATALYSTS | Ciba SC Holding AG (CH) | 2000-04-19 | — | — | EP | disclosed |
| WO-1999000397-A1 | RUTHENIUM AND OSMIUM CATALYSTS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 1999-01-07 | — | — | WO | disclosed |
| US-4260552-A | INSECTICIDES, HERBICIDES | UNIROYAL, INC. (US) | 1981-04-07 | — | — | US | disclosed |
| US-4160846-A | Method for controlling insects with tetrasubstituted organotin compounds | UNIROYAL, INC. (US) | 1979-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261451-A1 | Latent, high-activity olefin metathesis catalysts containing an N-heterocyclic carbene ligand | CDK8, LTC4S, ZCCHC8 | SMN1; SMN2 4544/4885CCR1 1440/4885CCR8 251/4885 |
| US-20130296511-A1 | LATENT, HIGH-ACTIVITY OLEFIN METATHESIS CATALYSTS CONTAINING AN N-HETEROCYCLIC CARBENE LIGAND | CDK8, LTC4S, ZCCHC8 | SMN1; SMN2 4544/4885CCR1 1440/4885CCR8 251/4885 |
| US-20150141603-A1 | LATENT, HIGH-ACTIVITY OLEFIN METATHESIS CATALYSTS CONTAINING AN N-HETEROCYCLIC CARBENE LIGAND | CDK8, LTC4S, ZCCHC8 | SMN1; SMN2 4544/4885CCR1 1440/4885CCR8 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.